                               SEQUENCE LISTING

<110> REVANCE THERAPEUTICS, INC.
 
<120> METHODS OF TREATMENT FOR CERVICAL DYSTONIA

<130> 13720.105001CD

<140>  
<141>  

<160> 10    

<170> PatentIn version 3.5

<210> 1
<211> 51
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide


<220>
<221> MISC_FEATURE
<222> (1)..(20)
<223> This region may encompass 0-20 'Gly' residues
      wherein some positions may be absent

<220>
<221> MISC_FEATURE
<222> (32)..(51)
<223> This region may encompass 0-20 'Gly' residues
      wherein some positions may be absent

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 1
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly 
1               5                   10                  15      


Gly Gly Gly Gly Arg Gly Arg Asp Asp Arg Arg Gln Arg Arg Arg Gly 
            20                  25                  30          


Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly 
        35                  40                  45              


Gly Gly Gly 
    50      


<210> 2
<211> 51
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide


<220>
<221> MISC_FEATURE
<222> (1)..(20)
<223> This region may encompass 0-20 'Gly' residues
      wherein some positions may be absent

<220>
<221> MISC_FEATURE
<222> (32)..(51)
<223> This region may encompass 0-20 'Gly' residues
      wherein some positions may be absent

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 2
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly 
1               5                   10                  15      


Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly 
            20                  25                  30          


Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly 
        35                  40                  45              


Gly Gly Gly 
    50      


<210> 3
<211> 49
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide


<220>
<221> MISC_FEATURE
<222> (1)..(20)
<223> This region may encompass 0-20 'Gly' residues
      wherein some positions may be absent

<220>
<221> MISC_FEATURE
<222> (30)..(49)
<223> This region may encompass 0-20 'Gly' residues
      wherein some positions may be absent

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 3
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly 
1               5                   10                  15      


Gly Gly Gly Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly 
            20                  25                  30          


Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly 
        35                  40                  45              


Gly 
    


<210> 4
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide

<400> 4
Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Lys Lys Lys Lys Lys Lys 
1               5                   10                  15      


Lys Lys Lys Lys Lys Lys Lys Lys Lys Gly Arg Lys Lys Arg Arg Gln 
            20                  25                  30          


Arg Arg Arg 
        35  


<210> 5
<211> 45
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide


<220>
<221> MISC_FEATURE
<222> (1)..(20)
<223> This region may encompass 0-20 'Gly' residues
      wherein some positions may be absent

<220>
<221> MISC_FEATURE
<222> (21)..(45)
<223> This region may encompass 5, 7, 9, 11, 13, 15, 17, 21, 23
      or 25 'Arg' residues wherein some positions may be absent

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 5
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly 
1               5                   10                  15      


Gly Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg 
            20                  25                  30          


Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg 
        35                  40                  45  


<210> 6
<211> 19
<212> PRT
<213> Drosophila sp.

<400> 6
Ser Gly Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp 
1               5                   10                  15      


Lys Lys Cys 
            


<210> 7
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide

<400> 7
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Lys Lys Lys Lys 
1               5                   10                  15      


Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Gly Tyr Gly Arg Lys 
            20                  25                  30          


Lys Arg Arg Gln Arg Arg Arg 
        35                  


<210> 8
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide

<400> 8
Arg Gly Arg Asp Asp Arg Arg Gln Arg Arg Arg Gly Lys Lys Lys Lys 
1               5                   10                  15      


Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Gly Arg Gly Arg Asp 
            20                  25                  30          


Asp Arg Arg Gln Arg Arg Arg 
        35                  


<210> 9
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MISC_FEATURE
<222> (1)..(20)
<223> This sequence may encompass 10-20 'Lys' residues
      wherein some positions may be absent

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 9
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1               5                   10                  15      


Lys Lys Lys Lys 
            20  


<210> 10
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 10
Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg 
1               5                   10  



